INTRATUMORAL CORRELATION OF MULTIPLEX IMMUNOFLUORESCENCE AND 89ZR-CREFMIRLIMAB BERDOXAM IMMUNOPET IN RECURRENT GBM PATIENTS TREATED WITH NEOADJUVANT ANTI-PD-1+/- ANTI-CTLA-4 THERAPY

被引：0
|
作者：
Markus, Lauren [1 ]
Sun, Lu [1 ]
Hugo, Willy [1 ]
Van den Abbeele, Annick D. [2 ]
Wen, Patrick [3 ]
Prins, Robert [4 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[4] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IMMU-38
引用
收藏
页数：1
相关论文
共 42 条
  • [21] Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma
    Duerinck, Johnny
    Lescrauwaet, Louise
    Dirven, Iris
    Del'haye, Jacomi
    Stevens, Latoya
    Geeraerts, Xenia
    Vaeyens, Freya
    Geens, Wietse
    Brock, Stefanie
    Vanbinst, Anne-Marie
    Everaert, Hendrik
    Caljon, Ben
    Bruneau, Michael
    Lebrun, Laetitia
    Salmon, Isabelle
    Kockx, Marc
    Tuyaerts, Sandra
    Neyns, Bart
    NEURO-ONCOLOGY, 2024, 26 (12) : 2208 - 2221
  • [22] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
    Bowyer, Samantha
    Prithviraj, Prashanth
    Lorigan, Paul
    Larkin, James
    McArthur, Grant
    Atkinson, Victoria
    Millward, Michael
    Khou, Muoi
    Diem, Stefan
    Ramanujam, Sangeetha
    Kong, Ben
    Liniker, Elizabeth
    Guminski, Alexander
    Parente, Phillip
    Andrews, Miles C.
    Parakh, Sagun
    Cebon, Jonathan
    Long, Georgina V.
    Carlino, Matteo S.
    Klein, Oliver
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15
  • [23] Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
    Samantha Bowyer
    Prashanth Prithviraj
    Paul Lorigan
    James Larkin
    Grant McArthur
    Victoria Atkinson
    Michael Millward
    Muoi Khou
    Stefan Diem
    Sangeetha Ramanujam
    Ben Kong
    Elizabeth Liniker
    Alexander Guminski
    Phillip Parente
    Miles C Andrews
    Sagun Parakh
    Jonathan Cebon
    Georgina V Long
    Matteo S Carlino
    Oliver Klein
    British Journal of Cancer, 2017, 116 : e15 - e15
  • [24] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
    Wagner, Nikolaus B.
    Forschner, Andrea
    Leiter, Ulrike
    Garbe, Claus
    Eigentler, Thomas K.
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 339 - 346
  • [25] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
    Nikolaus B Wagner
    Andrea Forschner
    Ulrike Leiter
    Claus Garbe
    Thomas K Eigentler
    British Journal of Cancer, 2018, 119 : 339 - 346
  • [26] Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
    Ahmed, K. A.
    Abuodeh, Y. A.
    Echevarria, M. I.
    Arrington, J. A.
    Stallworth, D. G.
    Hogue, C.
    Naghavi, A. O.
    Kim, S.
    Kim, Y.
    Patel, B. G.
    Sarangkasiri, S.
    Johnstone, P. A. S.
    Sahebjam, S.
    Khushalani, N. I.
    Forsyth, P. A.
    Harrison, L. B.
    Yu, M.
    Etame, A. B.
    Caudell, J. J.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2288 - 2294
  • [27] Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.
    Wen, Xizhi
    Zhang, Xiaoshi
    Ding, Ya
    Li, Dandan
    Li, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] MULTI-OMICS ANALYSIS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ANTI-PD-L1 PLUS ANTI-CTLA-4 AND LOCOREGIONAL THERAPY: CORRELATIVE STUDY OF PHASE2 TRIAL
    Myojin, Yuta
    Babei, Sepideh
    Hoffman, Christoph
    Kedei, Noemi
    Ruf, Benjamin
    Benmebarek, Mohamed-Reda
    Bauer, Kylynda
    Huang, Patrick
    Trehan, Rajiv
    Ma, Chi
    Monge, Cecilia
    Xie, Changqing
    Armstrong, Paul
    Duffy, Austin
    Korangy, Firouzeh
    Claassen, Manfred
    Greten, Tim
    HEPATOLOGY, 2024, 80
  • [29] Neoadjuvant combined anti-PD-1 and anti-CTLA-4 inhibitor therapy for locally-advanced resectable head and neck squamous cell carcinoma: systematic review and meta-analysis
    Shin, Donghoon
    Park, Robin
    Lee, Sunggon
    Lee, Woo Joo
    Yu, James
    Shahzad, Moazzam
    Rabinowits, Guilherme
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [30] A REPEATED INTRACRANIAL ADMINISTRATION OF ANTI-PD-1 ALONE OR IN COMBINATION WITH ANTI-CTLA-4 IMMUNE CHECKPOINT-BLOCKING MONOCLONAL ANTIBODIES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
    Lescrauwaet, L.
    Dirven, I
    Del'haye, J.
    Geens, W.
    Geeraerts, X.
    Stevens, L.
    Brock, S.
    Kockx, M.
    Seynaeve, L.
    Everaert, H.
    Vanbinst, A.
    Tuyaerts, S.
    Neyns, B.
    Duerinck, J.
    NEURO-ONCOLOGY, 2024, 26 : V17 - V17
12345